Td Asset Management Inc Iveric Bio, Inc. Transaction History

Td Asset Management Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	BUY	$18.67 - $24.56 $1.14 Million - $1.49 Million	60,800 Added 37.43%	223,218 $5.43 Million
Q4 2022 Feb 06, 2023	BUY	$17.24 - $23.95 $379,142 - $526,708	21,992 Added 15.66%	162,418 $3.48 Million
Q3 2022 Nov 07, 2022	SELL	$9.4 - $18.59 $107,432 - $212,465	-11,429 Reduced 7.53%	140,426 $2.43 Million
Q2 2022 Aug 04, 2022	SELL	$9.12 - $18.9 $489,971 - $1.02 Million	-53,725 Reduced 26.13%	151,855 $1.46 Million
Q1 2022 May 10, 2022	SELL	$12.15 - $16.83 $147,015 - $203,642	-12,100 Reduced 5.56%	205,580 $3.46 Million
Q3 2021 Nov 09, 2021	BUY	$7.07 - $17.5 $154,111 - $381,465	21,798 Added 11.13%	217,680 $3.54 Million
Q2 2021 Aug 11, 2021	BUY	$5.69 - $7.17 $229,022 - $288,592	40,250 Added 25.86%	195,882 $1.69 Million
Q1 2021 May 14, 2021	BUY	$5.08 - $6.89 $185,191 - $251,174	36,455 Added 30.59%	155,632 $962,000
Q3 2020 Nov 10, 2020	SELL	$4.01 - $6.29 $25,315 - $39,708	-6,313 Reduced 5.03%	119,177 $672,000
Q2 2020 Aug 13, 2020	BUY	$3.06 - $6.6 $383,999 - $828,234	125,490 New	125,490 $640,000

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Td Asset Management Inc with notifications on news.